PCSK9 and atherosclerosis: Our study has revealed other mechanisms of action responsible for cilostazol-related favorable effects on the lipid profile and anti-atherosclerosis in obese conditions by reducing PCSK9 and enhancing LDLR, supporting its therapeutic application in such a clinical setting.